肝胆相照论坛

标题: 激素替代疗法与乙型肝炎绝经后妇女的肝细胞癌风险降低和 [打印本页]

作者: StephenW 时间: 2022-7-22 12:48 标题: 激素替代疗法与乙型肝炎绝经后妇女的肝细胞癌风险降低和

激素替代疗法与乙型肝炎绝经后妇女的肝细胞癌风险降低和生存率提高有关：一项全国性的长期人群队列研究
Chun-Hsiang Wang 1 2 , Ruey-Chang Lin 1 , Hua-Yin Hsu 3 , Yuan-Tseng Tseng 4
隶属关系
隶属关系

1
台湾台南市立医院肝肠内科（由秀全医疗集团管理）。
2
台湾台南中华医科大学视光学系。
3
台湾台南市台南市立医院护理科（由秀全医疗股份有限公司管理）。
4
台湾台南市立医院医学研究委员会（由秀全医疗公司管理）。

PMID：35862398 DOI：10.1371/journal.pone.0271790

抽象的

感染乙型肝炎病毒 (HBV) 的绝经后妇女更有可能加速肝纤维化，最终发展为肝硬化或肝细胞癌 (HCC)。性激素与 HBV 相关 HCC 风险之间的关联尚不清楚。我们调查了激素替代疗法 (HRT) 是否对感染 HBV 的绝经后妇女有益。本回顾性研究从台湾国民健康保险研究数据库中选取了 2000 年 1 月至 2018 年 12 月期间 44,465 例 HBV 感染患者的数据。在排除既往患有肝病、肝硬化或肝脏恶性肿瘤的患者后，我们将剩余的 10,474 名患者按照是否接受 HRT 至少 3 个月（n = 5,638）和是否未接受 HRT（n = 4,836）进行分组。在倾向得分匹配后，我们将 3080 名患者分配到 HRT 队列，并将他们（1:1）与非 HRT 队列中的患者进行匹配。 HRT 队列的 HCC 发病率 (P < 0.022) 和全因死亡率 (P < 0.001) 低于非 HRT 队列。 HRT 队列的肝硬化风险没有显着升高（P = 0.355）。 HRT 与降低 HCC 风险和改善生存结果相关，但与绝经后妇女的肝硬化发展无关。
利益冲突声明

作者已声明不存在相互竞争的利益。

作者: StephenW 时间: 2022-7-22 12:49

Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study
Chun-Hsiang Wang 1 2 , Ruey-Chang Lin 1 , Hua-Yin Hsu 3 , Yuan-Tsung Tseng 4
Affiliations
Affiliations

1
Department of Hepatogastroenterology, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan.
2
Department of Optometry, Chung Hwa Medical University, Tainan, Taiwan.
3
Departments of Nursing, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan City, Taiwan.
4
Committee of Medical Research, Tainan Municipal Hospital (Managed by Show Chwan Medical Care Corporation), Tainan, Taiwan.

PMID: 35862398 DOI: 10.1371/journal.pone.0271790

Abstract

Postmenopausal women with hepatitis B virus (HBV) infection are more likely to have accelerated liver fibrosis, eventually advancing to liver cirrhosis or hepatocellular carcinoma (HCC). The association between sex hormones and HBV-related HCC risk is unclear. We investigated whether hormone replacement therapy (HRT) is beneficial to postmenopausal women with HBV infection. This retrospective study selected the data of 44,465patients with HBV infection between January 2000 and December 2018 from Taiwan's National Health Insurance Research Database. After excluding patients with preexisting liver diseases, liver cirrhosis, or liver malignancies, we grouped the remaining 10,474 patients by whether they had undergone HRT for at least 3 months (n = 5,638) and whether they had not received HRT (n = 4,836). After propensity score matching, we assigned 3080 patients to an HRT cohort and matched them (1:1) with those in a non-HRT cohort. The incidence of HCC (P < 0.022) and all-cause mortality rate (P < 0.001) were lower in the HRT cohort than in the non-HRT cohort. The liver cirrhosis risk was not significantly higher in the HRT cohort (P = 0.355). HRT is associated with reduced HCC risk and improved survival outcomes but is unrelated to liver cirrhosis development in postmenopausal women.
Conflict of interest statement

The authors have declared that no competing interests exist.

作者: Joebruin 时间: 2022-7-22 23:41

我现在每周吃1-2包edamame, 不知有没有用。

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)